EP-1492: Bowel and anal sphincter function after neoadjuvant chemoradiotherapy in rectal cancer patients

Rosa, C.; Caravatta, L.; Tommaso, M. Di; Ursini, Lucia Anna; Allajbej, A.; I, Zecca; Nicola, Massimo Di; Genovesi, Domenico

doi:10.1016/s0167-8140(18)31801-2

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, six patients suffered from temporary-to-permanent conversion of their stoma for different reasons. Rosa et al [ 28 ] found that most patients could retain relatively good rectal function after NAT. Ghiselli et al [ 29 ] observed that female and elderly patients might suffer from worse sphincter function after NAT.…”

Section: Discussionmentioning

confidence: 99%

Retrospective research of neoadjuvant therapy on tumor-downstaging, post-operative complications, and prognosis in locally advanced rectal cancer

Li¹,

Zhao²,

Feng³

et al. 2021

WJGS

View full text Add to dashboard Cite

BACKGROUND Neoadjuvant therapy (NAT) is becoming increasingly important in locally advanced rectal cancer. Hence, such research has become a problem. AIM To evaluate the downstaging effect of NAT, its impact on postoperative complications and its prognosis with different medical regimens. METHODS Seventy-seven cases from Shanghai Ruijin Hospital affiliated with Shanghai Jiaotong University School of Medicine were retrospectively collected and divided into the neoadjuvant radiochemotherapy (NRCT) group and the neoadjuvant chemotherapy (NCT) group. The differences between the two groups in tumor regression, postoperative complications, rectal function, disease-free survival, and overall survival were compared using the χ 2 test and Kaplan-Meier analysis. RESULTS Baseline data showed no statistical differences between the two groups, whereas the NRCT group had a higher rate of T4 (30/55 vs 5/22, P < 0.05) than the NCT groups. Twelve cases were evaluated as complete responders, and 15 cases were evaluated as tumor regression grade 0. Except for the reduction rate of T stage (NRCT 37/55 vs NCT 9/22, P < 0.05), there was no difference in effectiveness between the two groups. Preoperative radiation was not a risk factor for poor reaction or anastomotic leakage. No significant difference in postoperative complications and disease-free survival between the two groups was observed, although the NRCT group might have better long-term overall survival. CONCLUSION NAT can cause tumor downstaging preoperatively or even complete remission of the primary tumor. Radiochemotherapy could lead to better T downstaging and promising overall survival without more complications.

show abstract

Section: Discussionmentioning

confidence: 99%